Abstract P1-05-23: An observational cohort study of Multiplex8+: a spatially informed assay that uses multiplexed RNA-FISH guided laser capture microdissection followed by total RNA-sequencing

Evan D. Paul, Barbora Huraiová, Natália Matyašovská, Daniela Gábrišová, Soňa Gubová, Tomáš Ondris, Michal Gala, Liliane Barroso, Helena Ignačáková, Natália Valková, Fresia Pareja, Jakob Nikolas Kather, Pavol ČekanClinical 2025 · DOI

Abstract

Abstract We previously developed and validated a breast cancer (BCa) diagnostic test called mFISHseq on a retrospective cohort of 1,082 FFPE breast tissues. The test utilizes a multiplexed RNA-FISH panel consisting of estrogen (ESR1), progesterone (PGR), and HER2 (ERBB2) receptors and Ki67 (MKI67) to characterize regions of interest that are subsequently captured by laser capture microdissection for total RNA-SEQ. Here, we report the results from 53 patients that underwent a research use only (RUO) version of the test called Multiplex8+, which provides information about the four main BCa biomarkers, intrinsic molecular and TNBC subtypes, prognostic risk, and expression of 40 genes and 28 gene signatures that inform about cancer hallmark pathways and treatment response to chemotherapies as well as targeted therapies (e.g., immunotherapy, CDK4/6 inhibitors, and antibody drug-conugates (ADCs)). Three patients had two specimens (primary and metastatic tumor specimens) processed yielding a total of 56 patient specimens, which consisted of hormone receptor positive (HR+)/HER2− (n=11), HR+/HER2+ (n=9), HR−/HER2+ (n=4), and HR−/HER2− (n=30) as determined by IHC. Two patients had unavialable IHC data. The median age at surgery was 46 yrs and the patients comprised various node statuses (negative=17, positive=18, unavailable=21), tumor sizes (pT1=22, pT2-4=17, unavailable=17), and grades (G1=1, G2=16, G3=30, unavailable=9). Multiplex8+ showed high agreement with 90.5% of IHC reported results. Agreement was highest for HER2-ERBB2 (96.4%) followed by PR-PGR (92.7%), ER-ESR1 (85.5%), and Ki67-MKI67 (85.3%). Most discordant results for hormone receptors were in gray zone areas for IHC (i.e., ER/PR low ≤10%) and Multiplex8+ classified them as negative. Notably, two patients were classified as basal-like by intrinsic subtyping (both mesenchymal (M) TNBC subtype) and had high expression of proliferation, immune, and/or angiogenesis signatures. Another patient was classified as HER2 overexpressed and had elevated HER2 amplicon signatures and low luminal pathway signatures. This suggests that Multiplex8+ reflected the underlying tumor biology better than IHC. Follow up data for 20 patients revealed insights into the ultility of genes and gene signatures in predicting risk of relapse and response to treatment. Multiplex8+ was correct in predicting treatment sensitivity or resistance in 77% (17/22) of instances, which spanned chemotherapy, endocrine, anti-Her2, and novel targeted therapies. For example, one metastatic TNBC patient who had an excellent response to bevacizumab had two heterogeneous regions dissected using LCM and both regions had high levels of a hypoxia/inflammation/angiogenesis signature previously shown to predict sensitivity to bevacizumab. This patient also had high TACSTD2 and TOP1 the antigen and payload targets of the ADC, sacituzumab govitecan (SG). Notably, after progressing on bevacizumab, this patient responded well to SG, highlighting the value of this test in predicting response to more than one line of therapy. Another patient with metastatic HR+/HER2− BCa had a low (neo)adjuvant chemotherapy response signature as well as a high E2F4 signature that was previously shown to predict resistance to aromatase inhibitors and sensitivity to CDK4/6 inhibitors. Indeed, this patient had a poor response to aromatase inhibitors and chemotherapy, relapsing 2 months after surgery, but then had a beneficial response to CDK4/6 inhibitors. These examples, and other patient vignettes that will be discussed, demonstrate the clinical potential of Multiplex8+ by providing unique insights for each patient that could identify potential treatments (including subsequent lines of therapy) and explain why prior treatments performed poorly. The specimens in this observational study were obtained with the patients informed consent and the study was approved by the Ethics Committee of the Bratislava Self-Governing Region (Ref. No. 05320/2020/HF). Citation Format: Evan Paul, Barbora Huraiová, Natália Matyašovská, Daniela Gábrišová, Soňa Gubová, Tomáš Ondris, Michal Gala, Liliane Barroso, Helena Ignačáková, Natália Valková, Fresia Pareja, Jakob N. Kather, Pavol Čekan. An observational cohort study of Multiplex8+: a spatially informed assay that uses multiplexed RNA-FISH guided laser capture microdissection followed by total RNA-sequencing [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P1-05-23.
BibTeX
@inproceedings{paul2025abstract,
  author = {Evan D. Paul and Barbora Huraiová and Natália Matyašovská and Daniela Gábrišová and Soňa Gubová and Tomáš Ondris and Michal Gala and Liliane Barroso and Helena Ignačáková and Natália Valková and Fresia Pareja and Jakob Nikolas Kather and Pavol Čekan},
  title = {{Abstract P1-05-23: An observational cohort study of Multiplex8+: a spatially informed assay that uses multiplexed RNA-FISH guided laser capture microdissection followed by total RNA-sequencing}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1158/1557-3265.sabcs24-p1-05-23},
}

Loading related content...

Figure